Member Info for Bothwell

The company is on a sounder financial footing than ever before with a large fundraise at a horribly low price and a series of cost reductions which are intended to get the business to operating cash positive even if growth is limited this year. We continue to make decent progress in export sales but be hampered by a continuing decline in UK sales - since 2013 our UK sales of ODM have gone from �4.3m to just �1.5m despite it still being NHS policy to roll out ODM fully at pace and scale. Expecting the results of the largest ever trial of ODM to be published shortly and that these will give us the opportunity to push our story harder. At the same time we are in the process of changing the story a bit (to broaden the market and appeal to more doctors) as well as developing our products to broaden our offer. All in all, I would expect to see performance starting to improve this year and picking up momentum next.

Sent email to Jim and Jamie yesterday. Both sent back last time.

Please let us know how you get on. Anyone able to get hold of JM and see how long we are going to have to wait for this to take off. Been here since 2012. Tedious now. 6M shares in this for me.

Are we likely to wake up to a nice raise in the SP tomorrow morning? Getting me down now!

Just received the same one Matt.

I have sent an email to Jamie. If I don�t get a response the will contact Jim.

We confident that the product works due to nearly 25,000 exposures during clinical trials but Recordati will need to build the awareness around Premature Ejaculation.

It will be in the hands of Recordati whether or not Fortacin is successful in Europe as they are the licencee, not Plethora.

No chance it can be 10K per week. The share price would be well over 1HKD if that was the number. Happy if it is!

Recordati rolls out the launch of Fortacin in Europe in early 2018, it will eventually take over responsibility for the UK distribution including marketing and sales from Plethora.

What news are we waiting for?

We are starting to move again. Looking forward to European role out then USA here we come!

ODM+ as Part of Enhanced Recovery in Renal Transplantation 6th Sep 2017 ODM+ is recommended by NICE for use as part of an Enhanced Recovery Programme(ERP) to safely guide fluid and vasoactive/inotropic drugs. A new study demonstrates its value in patients with inherent haemodynamic complexities. The study challenges the belief among renal transplant clinicians that the principles of ER would be difficult to implement in chronic renal failure patients undergoing transplantation. The study (abstract here) looks at the outcomes when an ER programme is applied in renal transplantation. The study institution in Sheffield (UK) used Deltex ODM+ to guide fluid therapy as referenced by NICE and to reduce the use of central venous lines (apart from inotropic use). 286 patients were selected, with 135 in the ERP group and 151 in the traditional care group. Assessment included the quality of patient care and patient satisfaction. Results showed statistically significant reductions in postoperative pain, length of stay (LOS) for living donors, LOS for recipients and costs in the ERP group as well as better patient satisfaction. With 1-day hospital stay costing £513 in the NHS, reduction in LOS as a result of implementing ER saves £2052 per living-related transplant (4 days difference in the mean length of stay) and £2565 per deceased-donor transplant (5 days difference in the mean length of stay). Investigator comments The authors conclude “Our service evaluation demonstrated that enhanced recovery benefits both types of renal transplant (living and deceased grafts) procedures, with excellent patient satisfaction and reduction of hospital length of stay”. “We have to emphasize that ER does not only improve the quality of care of renal transplant patients but also provides other patients with advantages by reallocating the nursing and medical staff to look after critically ill patients in the current National Health Service environment of shortage of health care workers.”

Surprised to see no buying this morning.

I think there's a good case for pairing it with a firm such as Summit Therapeutics (LSE: SUMM), which released its interim results today. Well-cashed The drug discovery and development company is working on therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI). As with all early-stage drug development firms, the goal is to end up with a marketable product that can go on to generate revenue and profit, but such firms are known for burning cash and raising funds. However, Summit Therapeutics seems to have passed its most-precarious lossmaking stage. During October 2016, the firm signed up to an exclusive licence and collaboration agreement with Sarepta Therapeutics Inc. Sarepta and Summit will collaborate to develop therapies for patients with DMD and share R&D costs. Summit received $40m up front from Sarepta, which helped stabilise the company's financial position. The terms of the deal allow for potential future milestone payments to Summit of up to $522m. A bridge to commercialisation Summit also has an option to take up rights to the market in Latin America. Assuming that development goes well, it looks like it has a decent bridge to commercialisation in place and a route to market-generated revenues. Meanwhile, development progress is advanced. The firm expects to report results of a proof-of-concept trial for its potential DMD treatment, Ezutromoid in the first quarter of 2018 and to start phase 3 clinical trials with its C. difficile treatment Ridinilazole during the first half of 2018.

Released : 25 Aug 2017 14:30 Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 31 JULY 2017 ON 31 AUGUST 2017 Oxford, UK, · August 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the second quarter and half year ended 31 July 2017 on 31 August 2017. Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.

Really surprised the SP isn't moving higher.

Looking forward to Q1 in 2018. It is going to be a good year.

"Phase 1 funding of €50,000 may be followed by up to €2.5 million under Phase 2." The Phase 1 grant is expected to be received in H1 2017. The Company will be eligible to apply for Phase 2 as soon as it is able to demonstrate success from the feasibility work.

Deltex awarded EU Horizon 2020 Phase 1 grant Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that it has been awarded a grant of €50,000 under the EU's Horizon 2020 programme which finances feasibility studies for bringing new products on to the market. Per the European Commission's announcement (http://ec.europa.eu/unitedkingdom/news/sixteen-uk-smes-receive-eu-funding_en). "Deltex and Lariboisiere Hospital Paris have developed a system called TruVue which provides simultaneous visual display of a patient's aortic blood flow velocity and aortic blood pressure. It is expected to significantly contribute to patient safety. The EU funding will help Deltex test the system with users and collect feedback about their experience with the user interface, Graphical User Interface (GUI). It will also help work out the price of a multinational clinical trial for a phase 2 application."